In September 2013, the FDA unveiled new labeling recommendations for extended acting and prolonged release opioids requiring brands to get rid of reasonable pain as sign to be used, rather stating the drug is for "soreness serious sufficient to demand each day, around-the-clock, long-lasting opioid therapy".Naloxone can cut down the effects of over